COMUNICADO: Según un modelo matemático la vacunación podría reducir en un 80% los cánceres cervicales (y 2)

[3] Rogozza R, Estimating the clinical benefits of HPV- 16/18 vaccination: challenges of modeling predicted cases of cervical cancer in Poland and Mexico, two countries with differing degrees of cervical disease and population stability. Poster to be presented at ISPOR, 28-31 October 2006.

[4] Rash B, Comparing Management Patterns And Associated Costs Women With Abnormal Cervical Cytology In 5 Different Countries. Poster to be presented at ISPOR, 28-31 October 2006.

[5] Helms LJ, Melnikow J, Determing costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care 1999; 37:652-66.

[6] Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomarvirus-related disease. Am J Obstet Gynecol 2004; 191:114-20.

[7] De San José S et al. Adaptation of a Health Economic Model of the Natural History of HPV Infection and Cervical Cancer for Spain. Presented at International Papillomavirus Conference, Prague, 3-7 September 2006.

[8] Kohli M et al. Estimating the Long-term Impact of a Prophylactic Human Papillomavirus (HPV) 16/18 Vaccine on the Burden of Cervical Disease in the UK. Presented at International Papillomavirus Conference, Prague, 3-7 September 2006.

[9] Juday TR et al. Clinical Benefits Associated with Vaccination Against Human Papillomavirus: The Contribution of Cross-Protection . Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco (USA) (ICAAC), 27-30 September 2006.

Para más información, contactar con: GSK Biologicals: Chris Hunter-Ward, +32-2-656-3075, Stella Gu, +32-2-656-3533